Medtech Sector Primer

A medical device maker earns most of its value after the sale: from the procedures a placed system performs and the instruments, consumables and service each one pulls through. Revenue of that kind repeats for years, where a one-off equipment sale does not. Valuation therefore turns on organic growth from procedures and on how much of each year's profit has to be reinvested to fund it.

Medtech valuation benchmarks by recurring mix

The market pays for how long growth lasts, and repeat revenue from the installed base is the best evidence of that. The primer's screens move the multiple with the recurring share. They are illustrative market context, not thresholds to invest on.

The worked DCFs discount at 8.37-9.38%, built from an illustrative 4.50% Treasury yield, a 4.5-5.0% equity risk premium and after-tax debt. A company moves up its band with a longer growth runway and a higher return on the capital that funds growth. It moves down when reported growth leans on acquisitions: the primer flags any spread of more than three percentage points between reported and organic growth. For scale, the primer's illustrative range for diversified device portfolios is 22-32x forward earnings on 4-7% organic growth.

Worked example: a medtech franchise DCF

Take a hypothetical razor-blade franchise with $4.0B of revenue growing 14% a year organically for eight years, then fading to 4% by year 14. Operating margin climbs from 26% to 33%, and new growth capital earns a 28% return, so reinvestment takes half of each year's after-tax operating profit while growth runs at 14%. In year 1 that leaves $0.49B of free cash flow from $0.99B of profit. Cash flows are discounted at 9.38%.

The primer sets that against an illustrative $65 price, and the match is not the point. Re-run the DCF with four years of 14% growth instead of eight and value falls to $50.45; with twelve it rises to $82.60. The price pays for about eight years, so the analyst's job is to judge whether procedures and pull-through can deliver them.

Now change only the return on growth capital. At 20% instead of 28%, each year's growth needs more reinvestment and value per share falls to $56.61, 13% lower on the same revenue path. Growth bought at a thin return is worth less, and a flat multiple on revenue cannot see it.

The primer shows the 20-year schedule, a sensitivity grid across growth and the discount rate, and a diversified grower where the runway barely moves value. The Excel model does the same with your own inputs.

Which medtech valuation method fits which company

What the full primer adds

The primer builds the tools in order: how medtech makes money, the listed company types, the commercialisation ladder and the segments, then the revenue build and the cost side of margins and cash flow. A worked franchise DCF values two illustrative archetypes year by year, a razor-blade franchise and a diversified grower, with an installed-base build linking procedures to revenue and a runway table showing how many years of growth each price pays for. Applied cases cover pull-through and procedures, organic growth and acquisitions, and margins, and screening closes with recurring mix, organic growth and growth-adjusted P/E.

Free guides on the site cover the individual pieces, so you can revise one idea without reopening the PDF: razor-and-blade economics, organic vs reported growth, installed base and pull-through, growth-adjusted P/E, procedure volume economics, gross margins by company and GAAP against adjusted operating margin. Research profiles for Medtronic, Abbott, Intuitive Surgical, Stryker, Boston Scientific and Edwards Lifesciences run the same screens on filed results. The companion Excel model spans eleven sheets, from the two franchise valuations and a valuation summary through the installed-base build and the growth-adjusted P/E and organic-versus-reported checks to a live sensitivity grid, so changing organic growth or the return on capital re-runs the value.

Sheets: Quick Start, Instructions, Assumptions, Razor-Blade Franchise, Diversified Grower, Valuation Summary, Razor-Blade Build, Growth-Adj PE, Organic vs Reported, Sensitivity, Dashboard.